At the SPAC of Dawn
The latter half of 2023 has largely told a story of retrenchment in the SPAC market as much of the excess in the domain has found itself terminating and liquidating. But, the increase in outgoing has not completely canceled out the boom in incoming as three new SPACs filed to IPO yesterday alone.
Other bellwethers of a rebound have so far stayed away like deeper involvement of bulge bracket underwriters and veteran SPAC sponsors jumping back in with both feet. But, the impressive amount of fresh grass on the meadow does break from the gloomy fog of much of the year.
It also doesn’t hurt that 2023 is going out with two transactions that price de-SPACs above their combination valuation in successive weeks – well above in Cerevel’s case, without even a need to adjust for stock split changes.
News and Rumors
- PR: AbbVie (NYSE:ABBV) has agreed to acquire neuroscience drug developer Cerevel Therapeutics (NASDAQ:CERE) for $45 per share at a $8.7 billion in one of the most lucrative de-SPAC exits of all time. The deal may well vault the Arya team up the serial sponsor leader board where it already sits as the sixth-most successful team having completed three biotech deals between 2020 and 2021.
- Axios: X-energy, which canceled a combination with Ares virtually at the altar in October, has now raised $80 million in a private Series C for yet undisclosed terms.
Liquidations
-
InterPrivate III Financial Partners (NYSE:IPVF) has determined to redeem all of its outstanding shares of Class A common stock, effective as of December 21. As of the close of business on the last day of trading, December 8, the shares will be deemed cancelled and will represent only the rights to receive the per-share redemption price of approximately $10.75.
Terms Tracker for the Week Ending February 7, 2025 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. This past week saw one new SPAC IPO price, bringing the year-to-date total to nine. K&F Growth Acquisition Corp. II successfully debuted and managed to...
Retail enthusiasm has been a lifeblood of many SPAC transactions through to the combined companies’ ongoing lives as public companies, and several have taken to buying up Bitcoin as a way of keeping sometimes fickle retail investors engaged. Enterprise software MicroStrategy (NASDAQ:MSTR) pioneered this tactic before spot Bitcoin ETFs were available to the general public....
At the SPAC of Dawn The markets may still be figuring out their way in careening the early decisions of the new presidential administration, but one de-SPAC decided to cash in on at least one of them yesterday. Rare earth miner Critical Metals (NASDAQ:CRML) raised $22.5 million in a private placement taking advantage of a...
At the SPAC of Dawn The market may have sighed in relief with the postponement of tariffs, but they may not have gone too far into the background as the US also reported a record high $98.4 billion trade deficit for December yesterday, which came in more than $2 billion deeper than expected. More signals...
At the SPAC of Dawn Commentators may still spar over the level of positive impact SPACs have had in some sectors, but Peter Beck, CEO of Rocket Lab (NASDAQ:RKLB), believes the vehicles have been particularly positive for the space industry. Although he described the period as a “crazy, crazy time” when speaking at the Smallsat...